Moreno, AA, Presas-Rodríguez, S, Gonzalez-Garcia, AM, Teniente-Sera, A, Martínez-Cáceres, EM, Querol, L, Martín-Aguilar, L, Meca-Lallana, JE, Dos Santos, CE, Millán, J, López, GV, Orgaz, ATC, Ruiz, VC, Anunciación, BAJ, Hervas, JV, Ruiz, LB, Bravo, GCA, Ramo, C. Monitoring Patients with Relapsing-Remitting Multiple Sclerosis Switching from Intravenous to Subcutaneous Natalizumab every 4 Weeks vs every 6 Weeks. Multiple Sclerosis Journal. 2025; 31(3)DOI:. PMID:. IF:5.000(Q1/2D).

Luce, L, Kocak, G, Alonso-Pérez, J, Straub,, Töpf, A, Díaz-Manera, J. Cracking the code: genotype-phenotype correlation models in sarcoglycanopathies. NEUROMUSCULAR DISORDERS. 2025; 53DOI:. PMID:. IF:2.800(Q2/5D).

Unoje, O, Hussain, Y, Habib, A, Claeys, K, Gwathmey, K, Sahagian, G, Cortés-Vicente, E, Liu, L, Jimenez, R, Patel, M, Masschaele, D, Mantegazza, R, Meisel, A, Seth, A, Attarian, S. Sustained Clinical Efficacy and Long-Term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT. ANNALS OF NEUROLOGY. 2025; 98DOI:. PMID:. IF:7.700(Q1/1D).

Forcadell-Díez, L, Pérez, G, Fernández, A, Puig-Barrachina, V, Subirats, IG, Cortés, E, Moral, PD, Juárez, O. HOW TO PROMOTE HEALTHY AND EQUITABLE RELATIONSHIPS IN FORMAL EDUCATION: THEORETICAL FRAMEWORK AND EDUCATIONAL PROPOSAL. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).